Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TVTX
TVTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TVTX News
Leadership Transition at Travere Therapeutics
4d ago
Newsfilter
Travere Therapeutics Grants Equity Inducements to New Employees
Jun 11 2026
Newsfilter
Long-term Results of FILSPARI Show Significant Efficacy
Jun 04 2026
Newsfilter
Travere Licenses Civorebrutinib from Everest Medicines, Potential Best-in-Class Treatment
Jun 02 2026
stocktwits
Travere Therapeutics and Everest Medicines Sign $1.1B Licensing Agreement
Jun 02 2026
seekingalpha
Travere Therapeutics Grants Equity Inducements to New Employees
May 12 2026
Newsfilter
Roy D. Baynes Sells Shares in Travere Therapeutics Under 10b5-1 Plan
May 10 2026
Fool
Director Roy D. Baynes Sells Shares of Travere Therapeutics
May 10 2026
NASDAQ.COM
Travere Therapeutics Prices $475M Convertible Notes Offering
May 07 2026
seekingalpha
Travere Therapeutics Prices $475 Million Convertible Notes Offering
May 07 2026
Newsfilter
Analysis of XBI ETF Trading Dynamics
May 06 2026
NASDAQ.COM
Travere Therapeutics Plans $400 Million Convertible Notes Offering
May 05 2026
seekingalpha
Travere Therapeutics Plans $400 Million Convertible Notes Offering
May 05 2026
Yahoo Finance
Travere Therapeutics Reports Q1 Profit Exceeding Estimates
May 05 2026
Newsfilter
Travere Therapeutics Director Sells Shares Amid FDA Approval
Apr 20 2026
Fool
Travere Therapeutics Secures FDA Approval for Filspari
Apr 20 2026
Yahoo Finance
Show More News
